» Articles » PMID: 30048714

The G2019S Mutation in LRRK2 Imparts Resiliency to Kinase Inhibition

Overview
Journal Exp Neurol
Specialty Neurology
Date 2018 Jul 27
PMID 30048714
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

The G2019S mutation in LRRK2 is one of the most common known genetic causes of neurodegeneration and Parkinson disease (PD). LRRK2 mutations are thought to enhance LRRK2 kinase activity. Efficacious small molecule LRRK2 kinase inhibitors with favorable drug properties have recently been developed for pre-clinical studies in rodent models, and inhibitors have advanced to safety trials in humans. Rats that express human G2019S-LRRK2 protein and G2019S-LRRK2 knock-in mice provide newly characterized models to better understand the ostensible target for inhibitors. Herein, we explore the relationships between LRRK2 kinase inhibition in the brain and the periphery to establish the link between LRRK2 kinase activity and protein stability, induction of lysosomal defects in kidney and lung, and how G2019S-LRRK2 expression impacts these phenotypes. Using a novel ultra-sensitive scalable assay based on protein capillary electrophoresis with LRRK2 kinase inhibitors included in-diet, G2019S-LRRK2 protein was resilient to inhibition compared to wild-type (WT)-LRRK2 protein, particularly in the brain. Whereas WT-LRRK2 kinase activity could be completed blocked without lowering LRRK2 protein levels, higher inhibitor concentrations were necessary to fully reduce G2019S-LRRK2 activity. G2019S-LRRK2 expression afforded robust protection from inhibitor-induced kidney lysosomal defects, suggesting a gain-of-function for the mutation in this phenotype. In rodents treated with inhibitors, parallel measurements of phospho-Rab10 revealed a poor correlation to phospho-LRRK2, likely due to cells that express Rab10 but poorly express LRRK2 in heterogenous tissues and cell isolates. In summary, our results highlight several challenges associated with the inhibition of the G2019S-LRRK2 kinase that might be considered in initial clinical efforts.

Citing Articles

Single molecule array measures of LRRK2 kinase activity in serum link Parkinson's disease severity to peripheral inflammation.

Yuan Y, Li H, Sreeram K, Malankhanova T, Boddu R, Strader S Mol Neurodegener. 2024; 19(1):47.

PMID: 38862989 PMC: 11167795. DOI: 10.1186/s13024-024-00738-4.


Axonal Lysosomal Assays for Characterizing the Effects of LRRK2 G2019S.

Bhatia P, Bickle M, Agrawal A, Truss B, Nikolaidi A, Brockmann K Biology (Basel). 2024; 13(1).

PMID: 38275734 PMC: 10813644. DOI: 10.3390/biology13010058.


Inhibition of Parkinson's disease-related LRRK2 by type I and type II kinase inhibitors: Activity and structures.

Murillo M, Suarez A, Dederer V, Chatterjee D, Louro J, Knapp S Sci Adv. 2023; 9(48):eadk6191.

PMID: 38039358 PMC: 10691770. DOI: 10.1126/sciadv.adk6191.


A leucine-rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls.

Vissers M, Troyer M, Thijssen E, Pereira D, Heuberger J, Groeneveld G Clin Transl Sci. 2023; 16(8):1408-1420.

PMID: 37177855 PMC: 10432885. DOI: 10.1111/cts.13541.


LRRK2-Targeting Therapies March Through the Valley of Death.

West A, Schwarzschild M Mov Disord. 2023; 38(3):361-365.

PMID: 36942368 PMC: 11076002. DOI: 10.1002/mds.29343.


References
1.
West A . Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic. Mov Disord. 2014; 30(2):180-9. PMC: 4318704. DOI: 10.1002/mds.26075. View

2.
Cook D, Kannarkat G, Cintron A, Butkovich L, Fraser K, Chang J . LRRK2 levels in immune cells are increased in Parkinson's disease. NPJ Parkinsons Dis. 2017; 3:11. PMC: 5459798. DOI: 10.1038/s41531-017-0010-8. View

3.
Boddu R, Hull T, Bolisetty S, Hu X, Moehle M, Daher J . Leucine-rich repeat kinase 2 deficiency is protective in rhabdomyolysis-induced kidney injury. Hum Mol Genet. 2015; 24(14):4078-93. PMC: 4476452. DOI: 10.1093/hmg/ddv147. View

4.
Fan Y, Howden A, Sarhan A, Lis P, Ito G, Martinez T . Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils. Biochem J. 2017; 475(1):23-44. PMC: 5748842. DOI: 10.1042/BCJ20170803. View

5.
Tsika E, Nguyen A, Dusonchet J, Colin P, Schneider B, Moore D . Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease. Neurobiol Dis. 2015; 77:49-61. DOI: 10.1016/j.nbd.2015.02.019. View